Remdesivir (GS-5734) is a 10
-cyano-substituted adenosine nucleotide analogue prodrug that
shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently
under clinical development for the treatment of Ebola virus disease (EVD). While antiviral effects
have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola
virus (EBOV) inhibition for remdesivir remains to be fully elucidated. The EBOV RNA-dependent
RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochemical studies
with the relevant triphosphate (TP) form of remdesivir and its presumptive target. In this study, we
confirmed that remdesivir-TP is able... More
Remdesivir (GS-5734) is a 10
-cyano-substituted adenosine nucleotide analogue prodrug that
shows broad-spectrum antiviral activity against several RNA viruses. This compound is currently
under clinical development for the treatment of Ebola virus disease (EVD). While antiviral effects
have been demonstrated in cell culture and in non-human primates, the mechanism of action of Ebola
virus (EBOV) inhibition for remdesivir remains to be fully elucidated. The EBOV RNA-dependent
RNA polymerase (RdRp) complex was recently expressed and purified, enabling biochemical studies
with the relevant triphosphate (TP) form of remdesivir and its presumptive target. In this study, we
confirmed that remdesivir-TP is able to compete for incorporation with adenosine triphosphate (ATP).
Enzyme kinetics revealed that EBOV RdRp and respiratory syncytial virus (RSV) RdRp incorporate
ATP and remdesivir-TP with similar efficiencies. The selectivity of ATP against remdesivir-TP is ~4
for EBOV RdRp and ~3 for RSV RdRp. In contrast, purified human mitochondrial RNA polymerase
(h-mtRNAP) effectively discriminates against remdesivir-TP with a selectivity value of ~500-fold.
For EBOV RdRp, the incorporated inhibitor at position i does not affect the ensuing nucleotide
incorporation event at position i+1. For RSV RdRp, we measured a ~6-fold inhibition at position
i+1 although RNA synthesis was not terminated. Chain termination was in both cases delayed and
was seen predominantly at position i+5. This pattern is specific to remdesivir-TP and its 10
-cyano
modification. Compounds with modifications at the 20
-position show different patterns of inhibition.
While 20
-C-methyl-ATP is not incorporated, ara-ATP acts as a non-obligate chain terminator and
prevents nucleotide incorporation at position i+1. Taken together, our biochemical data indicate that
the major contribution to EBOV RNA synthesis inhibition by remdesivir can be ascribed to delayed
chain termination. The long distance of five residues between the incorporated nucleotide analogue
and its inhibitory effect warrant further investigation.